{"filing":{"accession_number":"0001104659-26-096404","cik":"0001962738","ticker":"CASIF","company_name":"CASI Pharmaceuticals, Inc.","form":"6-K","filing_date":"2026-08-14","report_date":"2026-08-14","primary_document":"tm2622837d2_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1962738/000110465926096404/tm2622837d2_6k.htm"},"events":[{"id":27711,"run_id":25288,"accession_number":"0001104659-26-096404","anchor_item_number":"EX-99.1","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This exhibit is a press release announcing CASI Pharmaceuticals' first-half 2026 business and financial results, dated August 14, 2026. It discloses revenues of $9.8 million, a net loss of $20.0 million, cash position of $3.8 million, and includes unaudited condensed consolidated balance sheets and statements of operations. The disclosure is material as it reports interim financial performance and includes significant operational updates (clinical trial progress, Nasdaq delisting, OTCQB quotation, and a $15 million convertible note financing).","company_name":"CASI Pharmaceuticals, Inc.","ticker":"CASIF","filing_date":"2026-08-14","form":"6-K","submitted_at":null,"items":[{"id":29358,"accession_number":"0001104659-26-096404","item_number":"EX-99.1","item_title":"tm2622837d2_ex99-1.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This exhibit is a press release announcing CASI Pharmaceuticals' first-half 2026 business and financial results, dated August 14, 2026. It discloses revenues of $9.8 million, a net loss of $20.0 million, cash position of $3.8 million, and includes unaudited condensed consolidated balance sheets and statements of operations. The disclosure is material as it reports interim financial performance and includes significant operational updates (clinical trial progress, Nasdaq delisting, OTCQB quotation, and a $15 million convertible note financing).","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-14T11:01:47.239022+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29358,"accession_number":"0001104659-26-096404","item_number":"EX-99.1","item_title":"tm2622837d2_ex99-1.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This exhibit is a press release announcing CASI Pharmaceuticals' first-half 2026 business and financial results, dated August 14, 2026. It discloses revenues of $9.8 million, a net loss of $20.0 million, cash position of $3.8 million, and includes unaudited condensed consolidated balance sheets and statements of operations. The disclosure is material as it reports interim financial performance and includes significant operational updates (clinical trial progress, Nasdaq delisting, OTCQB quotation, and a $15 million convertible note financing).","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-14T11:01:47.239022+00:00","company_name":"CASI Pharmaceuticals, Inc.","ticker":"CASIF","filing_date":"2026-08-14"}]}